Novel therapeutic options for Waldenström’s macroglobulinemia - 101793

Spotlight
Video

Novel therapeutic options for Waldenström’s macroglobulinemia

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: The therapeutic potential for Waldenström’s macroglobulinemia (WM) is widening, with our growing understanding and knowledge of the genetics behind this disease. In this interview at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, reviews the current and prospective therapies available for WM. He highlights the exciting work being done with BTK inhibitors and monoclonal antibodies, including acalabrutinib, venetoclax and daratumumab, which are advancing the repertoire of targeted therapies.
Shared By : VJHemOnc
Posted on : 07/20/18
Added : 10 months ago